drugset
drugset / Trial / NCT05426174

Study to Assess the Safety and Immunogenicity of Monovalent mRNA NA Vaccine in Adult Participants 18 Years of Age and Older

NCT05426174 ↗

Phase 1 Completed 233 enrolled Sanofi Pasteur, a Sanofi Company
RandomizedParallel-groupTriple-blindPrevention

Summary

This is a Phase I, first-in-human, randomized, modified double-blind, active-controlled, dose-escalation study to assess the safety and immunogenicity of up to 3 dose levels of mRNA NA vaccines, administered as a single IM injection in healthy adults aged 18 years and older. Two age groups, 18 to 64 years and ≥65 years, will be included in this study.

Timeline

Start
2022-06-09
Primary completion
2024-01-03
Completion
2024-01-03

Drugs

EvaluationDrugModalityDoseRoute
Comparator High Dose Quadrivalent Influenza Vaccine Vaccine — Intramuscular
Subject mRNA NA vaccine Messenger RNA (mRNA) — Intramuscular

Indications

No indication recorded.